Prevention of life-threatening arrhythmias by pharmacologic stimulation of the muscarinic receptors with oxotremorine

Geatano M. De Ferrari, Emilio Vanoli, Paola Curcuruto, Gianluca Tommasini, Peter J. Schwartz

Research output: Contribution to journalArticle

Abstract

The potential antiarrhythmic efficacy of pharmacologic parasympathetic activation is still controversial. This study assessed the antiarrhythmic effect of saline solution (n = 9) and of the muscarinic agonist oxotremorine (1.5 μg/kg administered intravenously) (n = 17) in a feline animal model in which malignant arrhythmias were reproducibly elicited by the combination of acute myocardial ischemia and left stellate ganglion stimulation. Although saline solution had no effect, oxotremorine significantly decreased heart rate, blood pressure, the incidence of ventricular fibrillation from 47% to 0% (p = 0.004), and the incidence of malignant arrhythmias (either ventricular tachycardia or ventricular fibrillation) from 88% to 12% (p <0.001). When reduction in heart rate was prevented by means of atrial pacing (n = 15), the incidence of malignant arrhythmias was still significantly reduced from 87% to 27% (p = 0.001). Arrhythmias were also graded as follows: 0 = no premature ventricular contractions; 1 = 1 to 10 premature ventricular contractions; 2 = 11 to 50 premature ventricular contractions; 3 = ventricular tachycardia; 4 = ventricular fibrillation. Arrhythmia severity was 3.29 ± 0.16 (SEM) in the control trials and was reduced to 0.76 ± 0.26 (p <0.001) by oxotremorine and to 1.53 ± 0.34 by oxotremorine and pacing (p = 0.002). Therefore a muscarinic agonist can significantly reduce malignant arrhythmias during acute myocardial ischemia and may represent a novel approach to the prevention of sudden cardiac death.

Original languageEnglish
Pages (from-to)883-890
Number of pages8
JournalAmerican Heart Journal
Volume124
Issue number4
DOIs
Publication statusPublished - 1992

Fingerprint

Oxotremorine
Muscarinic Receptors
Cardiac Arrhythmias
Ventricular Premature Complexes
Ventricular Fibrillation
Muscarinic Agonists
Ventricular Tachycardia
Sodium Chloride
Myocardial Ischemia
Incidence
Heart Rate
Stellate Ganglion
Sudden Cardiac Death
Felidae
Animal Models
Blood Pressure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Prevention of life-threatening arrhythmias by pharmacologic stimulation of the muscarinic receptors with oxotremorine. / De Ferrari, Geatano M.; Vanoli, Emilio; Curcuruto, Paola; Tommasini, Gianluca; Schwartz, Peter J.

In: American Heart Journal, Vol. 124, No. 4, 1992, p. 883-890.

Research output: Contribution to journalArticle

@article{3e217284c90440f8a6c4e0fd1c41258d,
title = "Prevention of life-threatening arrhythmias by pharmacologic stimulation of the muscarinic receptors with oxotremorine",
abstract = "The potential antiarrhythmic efficacy of pharmacologic parasympathetic activation is still controversial. This study assessed the antiarrhythmic effect of saline solution (n = 9) and of the muscarinic agonist oxotremorine (1.5 μg/kg administered intravenously) (n = 17) in a feline animal model in which malignant arrhythmias were reproducibly elicited by the combination of acute myocardial ischemia and left stellate ganglion stimulation. Although saline solution had no effect, oxotremorine significantly decreased heart rate, blood pressure, the incidence of ventricular fibrillation from 47{\%} to 0{\%} (p = 0.004), and the incidence of malignant arrhythmias (either ventricular tachycardia or ventricular fibrillation) from 88{\%} to 12{\%} (p <0.001). When reduction in heart rate was prevented by means of atrial pacing (n = 15), the incidence of malignant arrhythmias was still significantly reduced from 87{\%} to 27{\%} (p = 0.001). Arrhythmias were also graded as follows: 0 = no premature ventricular contractions; 1 = 1 to 10 premature ventricular contractions; 2 = 11 to 50 premature ventricular contractions; 3 = ventricular tachycardia; 4 = ventricular fibrillation. Arrhythmia severity was 3.29 ± 0.16 (SEM) in the control trials and was reduced to 0.76 ± 0.26 (p <0.001) by oxotremorine and to 1.53 ± 0.34 by oxotremorine and pacing (p = 0.002). Therefore a muscarinic agonist can significantly reduce malignant arrhythmias during acute myocardial ischemia and may represent a novel approach to the prevention of sudden cardiac death.",
author = "{De Ferrari}, {Geatano M.} and Emilio Vanoli and Paola Curcuruto and Gianluca Tommasini and Schwartz, {Peter J.}",
year = "1992",
doi = "10.1016/0002-8703(92)90968-2",
language = "English",
volume = "124",
pages = "883--890",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Prevention of life-threatening arrhythmias by pharmacologic stimulation of the muscarinic receptors with oxotremorine

AU - De Ferrari, Geatano M.

AU - Vanoli, Emilio

AU - Curcuruto, Paola

AU - Tommasini, Gianluca

AU - Schwartz, Peter J.

PY - 1992

Y1 - 1992

N2 - The potential antiarrhythmic efficacy of pharmacologic parasympathetic activation is still controversial. This study assessed the antiarrhythmic effect of saline solution (n = 9) and of the muscarinic agonist oxotremorine (1.5 μg/kg administered intravenously) (n = 17) in a feline animal model in which malignant arrhythmias were reproducibly elicited by the combination of acute myocardial ischemia and left stellate ganglion stimulation. Although saline solution had no effect, oxotremorine significantly decreased heart rate, blood pressure, the incidence of ventricular fibrillation from 47% to 0% (p = 0.004), and the incidence of malignant arrhythmias (either ventricular tachycardia or ventricular fibrillation) from 88% to 12% (p <0.001). When reduction in heart rate was prevented by means of atrial pacing (n = 15), the incidence of malignant arrhythmias was still significantly reduced from 87% to 27% (p = 0.001). Arrhythmias were also graded as follows: 0 = no premature ventricular contractions; 1 = 1 to 10 premature ventricular contractions; 2 = 11 to 50 premature ventricular contractions; 3 = ventricular tachycardia; 4 = ventricular fibrillation. Arrhythmia severity was 3.29 ± 0.16 (SEM) in the control trials and was reduced to 0.76 ± 0.26 (p <0.001) by oxotremorine and to 1.53 ± 0.34 by oxotremorine and pacing (p = 0.002). Therefore a muscarinic agonist can significantly reduce malignant arrhythmias during acute myocardial ischemia and may represent a novel approach to the prevention of sudden cardiac death.

AB - The potential antiarrhythmic efficacy of pharmacologic parasympathetic activation is still controversial. This study assessed the antiarrhythmic effect of saline solution (n = 9) and of the muscarinic agonist oxotremorine (1.5 μg/kg administered intravenously) (n = 17) in a feline animal model in which malignant arrhythmias were reproducibly elicited by the combination of acute myocardial ischemia and left stellate ganglion stimulation. Although saline solution had no effect, oxotremorine significantly decreased heart rate, blood pressure, the incidence of ventricular fibrillation from 47% to 0% (p = 0.004), and the incidence of malignant arrhythmias (either ventricular tachycardia or ventricular fibrillation) from 88% to 12% (p <0.001). When reduction in heart rate was prevented by means of atrial pacing (n = 15), the incidence of malignant arrhythmias was still significantly reduced from 87% to 27% (p = 0.001). Arrhythmias were also graded as follows: 0 = no premature ventricular contractions; 1 = 1 to 10 premature ventricular contractions; 2 = 11 to 50 premature ventricular contractions; 3 = ventricular tachycardia; 4 = ventricular fibrillation. Arrhythmia severity was 3.29 ± 0.16 (SEM) in the control trials and was reduced to 0.76 ± 0.26 (p <0.001) by oxotremorine and to 1.53 ± 0.34 by oxotremorine and pacing (p = 0.002). Therefore a muscarinic agonist can significantly reduce malignant arrhythmias during acute myocardial ischemia and may represent a novel approach to the prevention of sudden cardiac death.

UR - http://www.scopus.com/inward/record.url?scp=0026644748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026644748&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(92)90968-2

DO - 10.1016/0002-8703(92)90968-2

M3 - Article

C2 - 1382385

AN - SCOPUS:0026644748

VL - 124

SP - 883

EP - 890

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 4

ER -